Elevated advanced oxidation protein products levels in patients with liver cirrhosis

• Autorzy: Zuwala-Jagiello J. , Pazgan-Simon M. , Simon K. , Warwas M.
• Języki publikacji: EN

Abstrakty

EN

Serum concentrations of advanced oxidation protein products (AOPPs) and glycation end products (AGEs) were assessed with respect to functional compromise of liver, as determined by the Child-Pugh and MELD scores. Patients with decompensated liver cirrhosis (Child-Pugh B and C) exhibited significantly higher serum concentrations of AOPPs than both patients with compensated liver cirrhosis (Child-Pugh A) and controls. The levels of plasma AGEs in all liver cirrhotic patients were higher when compared with those with the controls and this difference was statistically significant. Plasma total antioxidant status of the patients was significantly lower than that of controls. Significant positive correlations between AOPPs level and the MELD score and between the oxidative stress index and the MELD score were found in all patients with liver cirrhosis. Altered AOPPs levels in decompensated patients may influence the potency of oxidative stress and the progression of liver disease.

Słowa kluczowe

EN

human disease; serum concentration; advanced oxidation protein product; cirrhosis; glycation; plasma level; patient; liver cirrhosis

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2009
• Tom: 56
• Numer: 4
• Opis fizyczny: p.679-685,ref.

Twórcy

autor

Zuwala-Jagiello J.

• Wroclaw Medical University, Szewska 38/39, 50-139 Wroclaw, Poland

autor

Pazgan-Simon M.

autor

Simon K.

autor

Warwas M.

Bibliografia

• Bandara P, George J, McCaughan G, Naidoo D, Lux O, Salonikas C, Kench J, Byth K, Farrell GC (2005) Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver Int 25: 518-526. 
• Bedossa P, Houglum K, Trautwein C, Holstege A, Chojkier M (1994) Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis? Hepatology 19: 1262-1271. 
• Benzie IF, Strain JJ (1999) Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Meth Enzymol 299: 15-27. 
• Bolukbas C, Bolukbas FF, Horoz M, Aslan M, Celik H, Erel O (2005) Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection. BMC Infect Dis 5: 95-102. 
• Canakci V, Yildirim A, Canakci CF, Eltas A, Cicek Y, Canakci H (2007) Total antioxidant capacity and antioxidant enzymes in serum, saliva, and gingival crevicular fluid of preeclamptic women with and without periodontal disease. J Periodontol 78: 1602-1611. 
• Cao G, Prior RL (1998) Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 44: 1309-1315. 
• Czeczot H, Scibior D, Skrzycki M, Podsiad M (2006) Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim Polon 53: 237-242. 
• Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R (2003) Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329: 23-38. 
• Denzer UW, Lüth S (2009) Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol 23: 453-460. 
• Eissa LA, Gad LS, Rabie AM, El-Gayar AM (2008) Thrombopoietin level in patients with chronic liver diseases. Ann Hepatol 7: 235-244. 
• Erel O (2004) A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37: 112-119. 
• Fierbinteanu-Braticevici C, Bengus A, Neamtu M, Usvat R (2002) The risk factors of fibrosis in nonalcoholic steatohepatitis. Rom J Intern Med 40: 81-88. 
• Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250. 
• Górka J, Zuwała-Jagiełło J, Pazgan-Simon M, Simon K, Warwas M (2008) Fluorescence of age in serum in detecting liver cirrhosis and hepatocellular carcinoma among patients with anti-HCV antibodies. Przegl Epidemiol 62: 393-400 (in Polish). 
• Gutteridge JM, Halliwell B (1994) Antioxidants in nutrition, health, and disease. pp 111-123. Oxford University Press, New York.
• Harma M, Harma M, Erel O (2003) Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly 133: 563-566. 
• Huo TI, Lin HC, Wu JC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD (2006) Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl 12: 65-71. 
• Hyogo H, Yamagishi S (2008) Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 14: 969-972. 
• Iwao Y, Anraku M, Hiraike M, Kawai K, Nakajou K, Kai T, Suenaga A, Otagiri M (2006) The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet 21: 140-146. 
• Kalousová M, Sulková S, Fialová L, Soukupová J, Malbohan IM, Spacek P, Braun M, Mikulíková L, Fortová M, Horejsí M, Tesar V, Zima T (2003) Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant 18: 2577-2581. 
• Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J (2005) Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 579: 37-46. 
• Koike K, Miyoshi H (2006) Oxidative stress and hepatitis C viral infection. Hepatol Res 34: 65-73. 
• Loguercio C, Federico A (2003) Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 34: 1-10. 
• Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland, A, Niwa, T, Lemke HD, Schinzel R (1997) Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35: 669-677. 
• Niki, E, Noguchi N (2000) Evaluation of antioxidant capacity. What capacity is being measured by which method? IUBMB Life 50: 323-329. 
• Oettl K, Stadlbauer V, Petter F, Greilberger J, Putz-Bankuti C, Hallström S, Lackner C, Stauber RE (2008) Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 1782: 469-473. 
• Peng K, Wu X, Zhao H, Sun Y (2006) Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Chin Med J (Engl) 119: 1088-1093. 
• Poli G, Parola M (1997) Oxidative damage and fibrogenesis. Free Rad Biol Med 22: 287-305. 
• Rice-Evans C, Miller NJ (1994) Total antioxidant status in plasma and body fluids. Meth Enzymol 234: 279-293. 
• Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Serra MA, Romero FJ (1998) Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Free Radic Biol Med 25: 993-997. 
• Sebekova KV, Kupcova R, Schinzel A, Heidland J (2002) Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J Hepatol 36: 66-71. 
• Servettaz A, Guilpain P, Goulvestre C, Chéreau C, Hercend C, Nicco C, Guillevin L, Weill B, Mouthon L, Batteux F (2007) Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 66: 1202-1209. 
• Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, Lotze MT (2009) RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7: 17-38. 
• Svistounov D, Smedsrød BJ (2004) Hepatic clearance of advanced glycation end products (AGEs) - myth or truth? J Hepatol 41: 1038-1040. 
• Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84. 
• Wiest R, Groszmann RJ (2002) The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35: 478-491. 
• Willcox JK, Ash SL, Catignani GL (2004) Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr 44: 275-295. 
• Witko-Sarsat V, Friedlander M, Capelliere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313. 
• Witko-Sarsat V, Friedlander M, Khoa TN, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer J-M, Jungers P, Drueke T, Descamps-Latscha B (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532. 
• Witko-Sarsat V, Gausson V, Nguyen A-T, Nguyen AT, Touam M, Drüeke T, Santangelo F, Descamps-Latscha B (2003) AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 64: 82-91. 
• Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS (2002) Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 97: 2634-2639. 
• Zuwała-Jagiełło J, Simon K, Pazgan-Simon M, Kość-Czarny A, Warwas M (2006) Advanced glycation end products in serum of patients with chronic hepatitis and liver cirrhosis. Adv Clin Exp Med 2: 259-264.
• Zuwała-Jagiełło J, Pazgan-Simon M, Górka J, Simon K, Milczarska J, Warwas M (2007) Serum advanced glycation end products and the development of hepatocellular carcinoma among HBV carriers. Pol J Environ Stud 16: 747-751 (in Polish).